PEN
Penumbra Inc
NYSE · Healthcare · Medical - Devices · US
$322.45
+0.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6B | 1.4B | 1.2B | 1.1B | 847.1M |
| Cost of Revenue | 499.5M | 461.2M | 439.6M | 375.9M | 311.9M |
| Gross Profit | 1.1B | 942.4M | 755.0M | 682.6M | 535.2M |
| Operating Expenses | |||||
| R&D Expense | 94.9M | 89.8M | 94.8M | 84.4M | 79.4M |
| SG&A Expense | 776.6M | 663.4M | 574.0M | 506.5M | 449.7M |
| General & Admin Expense | 204.2M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | 18.2M | — |
| Total Operating Expenses | 871.5M | 753.2M | 668.8M | 609.1M | 529.1M |
| Cost and Expenses | 1.4B | 1.2B | 1.1B | 985.0M | 841.1M |
| Operating Income (EBIT) | 189.2M | 189.2M | 86.2M | 73.6M | 6.1M |
| Non-Operating | |||||
| Interest Income | 21.5M | 16.3M | 13.7M | 6.8M | 1.9M |
| Interest Expense | 1.3M | 1.3M | 1.4M | 1.7M | 1.7M |
| Net Interest Income | 20.2M | 15.0M | 12.3M | 5.1M | 137.0K |
| Other Non-Op Income/Expense | 18.6M | 15.9M | (65.4M) | 6.1M | (2.2M) |
| Non-Operating Income (excl Interest) | (19.8M) | (17.2M) | 63.9M | (7.8M) | 441.0K |
| EBT (Pre-Tax Income) | 207.8M | 205.1M | 20.9M | 79.7M | 3.9M |
| Income Tax Expense | 50.8M | 27.4M | 6.9M | (11.3M) | 5.9M |
| Bottom Line | |||||
| Net Income | 157.0M | 177.7M | 14.0M | 91.0M | (2.0M) |
| Earnings from Cont. Ops | 157.0M | 177.7M | 14.0M | 91.0M | (2.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 157.0M | 177.7M | 14.0M | 91.0M | (2.0M) |
| Per Share | |||||
| Basic EPS | $3.99 | $4.57 | $0.36 | $2.37 | ($0.05) |
| Diluted EPS | $3.97 | $4.52 | $0.36 | $2.32 | ($0.05) |
| Revenue Per Share | $39.60 | $36.07 | $30.92 | $27.56 | $22.39 |
| Shares | |||||
| Basic Shares Outstanding | 39.4M | 38.9M | 38.6M | 38.4M | 37.8M |
| Diluted Shares Outstanding | 39.6M | 39.3M | 39.3M | 39.2M | 37.8M |
| Profitability Metrics | |||||
| EBITDA | 229.2M | 223.9M | 46.0M | 108.6M | 30.0M |
| D&A | 20.1M | 17.5M | 23.7M | 27.3M | 24.3M |
| EBIT | 209.1M | 206.4M | 22.3M | 81.4M | 5.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026